<DOC>
	<DOCNO>NCT00573040</DOCNO>
	<brief_summary>Our group show model study increase radiation dose pre-specified normal tissue dose constrains could lead increase TCP NTCP . In subsequent phase I trial , investigator show safety approach . Here , investigator want investigate efficacy prospective study patient stage I-III NSCLC , select radical radiotherapy</brief_summary>
	<brief_title>Radiotherapy NSCLC Individualized MLD</brief_title>
	<detailed_description>Eligible patient ( see ) receive radiotherapy primary tumor initially involve mediastinal lymph node follow MLD ( Mean Lung Dose ) : - MLD=19 Gy Fev1 DLCO &gt; 50 % predict value - MLD=15 Gy Fev1 and/or DLCO 40-49 % predict value - MLD=10 Gy Fev1 and/or DLCO &lt; 40 % predict value Other dose-constrains : spinal cord max : 54 Gy , brachial plexus ( Dmax ) :66 Gy Minimum tumor dose:79.2 Gy . Radiotherapy deliver twice-daily fraction 1.8 Gy 8 10 h interfraction-interval , 5 day per week . The radiation dose specify accord ICRU 50 . Lung density correction apply , well standard QA procedure . Technical requirement standard practice MAASTRO clinic .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological proven NSCLC UICC stage IIII Performance status 02 FeV 1 DLCO least 30 % agepredicted value Not NSCLC mixed NSCLC histology ( e.g . small cell carcinoma ) UICC stage IV Performance status 3 FeV 1 DLCO &lt; 30 % agepredicted value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Stage III non-small cell lung cancer</keyword>
</DOC>